Online Appendix for the following JACC article
TITLE: Cardiac Allograft Vasculopathy by Intravascular Ultrasound in Heart Transplant
Patients: Substudy From the Everolimus Versus Mycophenolate Mofetil Randomized,
Multicenter Trial
AUTHORS: Jon A. Kobashigawa, MD, Daniel F. Pauly, MD, PHD, Randall C. Starling, MD,
MPH, Howard Eisen, MD, Heather Ross, MD, Shoei-Shen Wang, MD, Bernard Cantin, MD,
PHD, James A. Hill, MD, MS, Patricia Lopez, MD, Gaohong Dong, PHD, Stephen Nichols,
MBBS, PhD, on behalf of the A2310 IVUS Substudy Investigators
APPENDIX
The RAD A2310 IVUS Substudy Study Principal Investigators and Co-Principal
Investigators
Argentina: Fundacion Favaloro, Buenos Aires—R. Favaloro, M. P. Lastra, L. Favaloro;
Sanatorio Parque, Santa Fe—J. Sgrosso, F. Diez; Australia: St Vincents Hospital,
Darlinghurst—E. Kotlyar, P. Macdonald, C. Hayward, C. Coveman, J. Suttie, S. Faddy, A.
Keogh; Belgium: Cliniques Universitaires Saint-Luc, Bruxelles—A. Poncelet, O.
Vancaeneghem, O. Gurné; Canada: Toronto General Hospital, Toronto— M. McDonald, D.
Delgado, V. Rao, H. Ross; Institut Univ. de cardiologie et pneumologie de Québec, SainteFoy—M-H. Leblanc, M. Senechal, B. Cantin; University of Alberta Hospital, Edmonton—J.
Burton, W. Tymchak, L. Lalonde, D. Kim; New Halifax Infirmary, Halifax—M. Rajda; France:
CHU De Strasbourg Hôpital Civil Medicale B, Strasbourg—E. Epailly; Hôpital Cardiologique
de Lyon—P. Boissonnat; CHU Hôpital de Brabois, Nancy—M-F. Mattei, Germany:
Universitaetsklinik Regensburg—T. Pühler, A. Haneya, L. Ruppecht , S. Hirt; Deutsches
Herzzentrum Berlin—M. Bettmann, U. Busch, B. Debus, S. Hornig, D. Van der Spek, H.
Lehmkuhl; Herz- u. Diabeteszentrum NRW/Ruhr-Universität Bochum—G. Tenderich, U.
Schultz, S. Eckert; Italy: Az.Ospedaliero-Universitaria S.Giovanni Battista di Torino— M.
Rinaldi, M. Ribezzo, F. Savia, M. La Torre, C. Barbero; Az.Osp.di Bologna Policl.S.OrsolaMalpighi Univ.degli Studi, Bologna—A. Branzi, L. Potena, M. Masetti, F. Grigioni; A.O.Università di Padova-Università degli Studi, Padova—G. Gerosa, G. Feltrin, C. D'Agostino;
Norway: Rikshospitalet, Hjertemedisinsk avdeling, Oslo—A. Andreassen, E. Gude; Spain:
Hospital Puerta De Hierro Majadahonda, Madrid—J. Segovia, L. Pulpon, M. Gómez, L. Silva;
Taiwan: National Taiwan University Hospital, Taipei— S-S. Wang, R-B. Hsu, N-K. Chou;
United Kingdom: Wythenshawe Hospital, Manchester—N. Yonan; Papworth Hospital,
Cambridge—J. Parameshwar; Queen Elizabeth Hospital, Birmingham—I. Wilson, M.
Mukadam; United States: University of Florida College of Medicine, Gainesville—J. Aranda, J.
Hill, R. Schofield, E. Handberg, D. Leach, D. F. Pauly; Cedars-Sinai Heart Institute, Los
Angeles—J. Kobashigawa; UCLA Medical Center, Los Angeles—G. Fonarow; Intermountain
Medical Center, Murray—D. Renlund, R. Alhareti, D. Budge, A. Kfoury; Medical University of
South Carolina, Charleston—A. Van Bakel, N. Pereira; Kaufman Center for Heart Failure,
Heart and Vascular Institute, Cleveland Clinic Foundation, Cleveland—J. Young, R. C.
Starling; Cleveland Clinic—S. J. Nicholls; Drexel University College of Medicine/Hahnemann
University Hospital, Philadelphia—S. Hankins, A. Berger, H.J. Eisen; Cardiovascular Center of
Puerto Rico and the Caribbean, San Juan—H. Banchs-Pieretti; Loyola University Medical
School, Maywood—A. Heroux; Penn State College of Medicine, Hershey—J. Boehmer;
Massachusetts General Hospital—M. Semigran; Recanati Miller Transplant Institute, New
York—S. Pinney; St Luke's Medical Center Cardiac Services, Milwaukee—T. Hastings, B.
Pisani, ; Emory University Hospital—W. Book.
Online Table 1. Incidence rates of patients with lipid abnormalities at 12 months posttransplant
Everolimus
1.5mg (%)
N=88
MMF (%)
N=101
Difference (95% CI)
for Everolimus 1.5mg
vs. MMF
Low (male): <40mg/dL
Low (female): <50mg/dL
74.3
83.3
83.0
100.0
-8.7 (-21.6, 4.2)
-16.7 (-33.9, 0.6)
LDL-cholesterol
High : ≥160 mg/dL
Very high: ≥190 mg/dL
33.0
22.7
22.8
6.9
10.2 (-2.6, 23.0)
15.8 (5.7, 25.9)
Total cholesterol
High: >240 mg/dL
58.0
35.6
22.3 (8.4, 36.2)
Triglycerides
High: ≥200 mg/dL
Very high: ≥500 mg/dL
83.0
8.0
64.4
10.8
18.6 (6.4, 30.8)
-1.9 (-10.1, 6.2)
Total cholesterol/
HDL-cholesterol
High: ≥5
Very high: >7
36.4
8.0
43.6
10.9
-7.2 (-21.1, 6.7)
-2.9 (-11.2, 5.4)
Variable
Notable criteria
HDL-cholesterol
MMF, mycophenolate mofetil; MIT, maximal intimal thickness.